Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Standard
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. / Alchalby, Haefaa; Yunus, Dinah-Rohina; Zabelina, Tatjana; Kobbe, Guido; Holler, Ernst; Bornhäuser, Martin; Schwerdtfeger, Rainer; Bethge, Wolfgang; Kvasnicka, Hans Michael; Büsche, Guntram; Ayuketang Ayuk, Francis; Bacher, Ulrike; Zander, Axel R.; Kröger, Nicolaus.
In: BRIT J HAEMATOL, Vol. 157, No. 1, 1, 2012, p. 75-85.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
AU - Alchalby, Haefaa
AU - Yunus, Dinah-Rohina
AU - Zabelina, Tatjana
AU - Kobbe, Guido
AU - Holler, Ernst
AU - Bornhäuser, Martin
AU - Schwerdtfeger, Rainer
AU - Bethge, Wolfgang
AU - Kvasnicka, Hans Michael
AU - Büsche, Guntram
AU - Ayuketang Ayuk, Francis
AU - Bacher, Ulrike
AU - Zander, Axel R.
AU - Kröger, Nicolaus
PY - 2012
Y1 - 2012
N2 - To define a prognostic model for predicting outcome of reduced-intensity allogeneic stem cell transplantation (RIC-ASCT) for myelofibrosis we evaluated 150 homogeneously treated patients and developed a new risk score for overall survival (OS). In a multivariate Cox model for OS, only JAK2 V617F wild-type, age ?57?years and constitutional symptoms were independently predictive for OS (Hazard Ratio: 2·02; 2·43 and 2·80 respectively). Depending on the presence of one, two or all of these factors, HR of death was 3·08; 4·70 and 16·61 respectively (P?<?0·001). This score was compared to the Lille, Cervantes, International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS) and modified European Blood and Marrow Transplantation Group (EBMT) scores. Lille score correlated significantly with OS but discriminated poorly between the intermediate and high-risk groups (5-year OS 56% and 51% respectively). IPSS and DIPSS correlated significantly with OS but differences between intermediate-1 and intermediate-2 groups were not significant (5-year OS 78% vs. 78% and 70%, 60% respectively). Modified EBMT and Cervantes models did not predict OS post-ASCT. In conclusion, a simple model which includes: age, JAK2 V617F-status and constitutional symptoms can clearly separate distinct risk groups and can be used in addition to the Lille model to predict OS after RIC-ASCT for myelofibrosis.
AB - To define a prognostic model for predicting outcome of reduced-intensity allogeneic stem cell transplantation (RIC-ASCT) for myelofibrosis we evaluated 150 homogeneously treated patients and developed a new risk score for overall survival (OS). In a multivariate Cox model for OS, only JAK2 V617F wild-type, age ?57?years and constitutional symptoms were independently predictive for OS (Hazard Ratio: 2·02; 2·43 and 2·80 respectively). Depending on the presence of one, two or all of these factors, HR of death was 3·08; 4·70 and 16·61 respectively (P?<?0·001). This score was compared to the Lille, Cervantes, International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS) and modified European Blood and Marrow Transplantation Group (EBMT) scores. Lille score correlated significantly with OS but discriminated poorly between the intermediate and high-risk groups (5-year OS 56% and 51% respectively). IPSS and DIPSS correlated significantly with OS but differences between intermediate-1 and intermediate-2 groups were not significant (5-year OS 78% vs. 78% and 70%, 60% respectively). Modified EBMT and Cervantes models did not predict OS post-ASCT. In conclusion, a simple model which includes: age, JAK2 V617F-status and constitutional symptoms can clearly separate distinct risk groups and can be used in addition to the Lille model to predict OS after RIC-ASCT for myelofibrosis.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Assessment
KW - Survival Rate
KW - Time Factors
KW - Disease-Free Survival
KW - Mutation, Missense
KW - Amino Acid Substitution
KW - Transplantation, Homologous
KW - Models, Biological
KW - Stem Cell Transplantation
KW - Transplantation Conditioning
KW - Janus Kinase 2/genetics/metabolism
KW - Primary Myelofibrosis/enzymology/genetics/mortality/therapy
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Assessment
KW - Survival Rate
KW - Time Factors
KW - Disease-Free Survival
KW - Mutation, Missense
KW - Amino Acid Substitution
KW - Transplantation, Homologous
KW - Models, Biological
KW - Stem Cell Transplantation
KW - Transplantation Conditioning
KW - Janus Kinase 2/genetics/metabolism
KW - Primary Myelofibrosis/enzymology/genetics/mortality/therapy
M3 - SCORING: Journal article
VL - 157
SP - 75
EP - 85
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 1
M1 - 1
ER -
